Benefit evidence and safety risk can both be true
Part 1 · outcome evidence
A product- and population-specific benefit
The labelled kidney indication applies to Ozempic in adults with type 2 diabetes and chronic kidney disease. [1] It does not establish that every GLP-1 protects every person.
Part 2 · safety warning
Volume depletion can create kidney risk
The Ozempic label warns about acute kidney injury due to volume depletion. Most postmarketing reports occurred after nausea, vomiting, diarrhea, or other gastrointestinal reactions led to dehydration. [1]
What FLOW actually found
FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease and followed them for a median of 3.4 years. Semaglutide lowered the relative risk of the primary composite outcome by 24% compared with placebo: 331 first events versus 410, with a hazard ratio of 0.76 (95% confidence interval, 0.66–0.88). [2]
The composite included kidney failure, a sustained eGFR decline of at least 50%, or death from kidney or cardiovascular causes. [2]
Two kidney measurements, two complementary views
NIDDK says providers use a blood test for GFR or eGFR and a urine albumin test or UACR to diagnose and monitor kidney disease. [3] These measurements describe different parts of the story; they are not a diagnosis generated by a tracker.
Blood
eGFR: filtration
A blood test is used to estimate GFR, which NIDDK describes as a check of how well the kidneys filter blood. [3]
Urine
UACR: albumin leakage
A urine albumin test checks for albumin in urine. NIDDK notes that an abnormal urine albumin result may be repeated to confirm it; what a result means belongs with the clinician. [3]
A neutral tracking framework
The useful record keeps events in sequence without trying to interpret them:
- 1. Copy each lab exactly. Record the lab name, value, units, reference range, date, and source.
- 2. Name the product. Record the exact medication or product name and any clinician-directed changes.
- 3. Time-stamp GI symptoms. Note nausea, vomiting, or diarrhea and whether fluids could be kept down.
- 4. Preserve sequence. Keep symptoms and labs in date order without assigning cause.
- 5. Carry questions forward. Bring unresolved questions to the prescriber.
What not to infer
The kidney benefit in FLOW does not erase the label’s kidney safety warning.
A symptom log cannot prove acute kidney injury.
One lab point does not establish why it changed.
A tracker cannot screen interactions or treatment suitability.
Questions for the prescriber
- Which kidney measurements matter for my condition and product?
- What change would you want reported?
- If gastrointestinal symptoms occur, what is the plan for contacting the office and labs?
- How should I record clinician-directed medication changes?
Keep the timeline legible
Put the plan, history, progress, and symptoms in context
Jabbit keeps clinician-directed injection schedules, reminders, injection history, progress, and symptom timing together. It does not interpret labs, diagnose kidney problems, or choose treatment.
Track your clinician-directed plan in JabbitFrequently asked questions
Does Ozempic protect the kidneys?
The current Ozempic label includes reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. In FLOW, semaglutide reduced the relative risk of the primary composite outcome by 24% versus placebo in that specific studied population. This is not a universal claim for every GLP-1 or every person. [1] [2]
Can semaglutide affect kidney safety?
Yes. The current Ozempic label warns about acute kidney injury due to volume depletion. Most postmarketing reports occurred after gastrointestinal reactions leading to dehydration, including nausea, vomiting, or diarrhea. [1]
Which kidney tests tell different parts of the story?
NIDDK describes eGFR, based on a blood test, as a view of kidney filtration and UACR, based on a urine albumin test, as a view of albumin leakage. They are complementary measurements, not a diagnosis from a tracker. [3]
Can Jabbit interpret kidney labs?
No. Jabbit keeps clinician-directed injection schedules, reminders, injection history, progress, and symptom timing together. It does not interpret labs, diagnose kidney problems, or choose treatment.
Sources opened and checked
- [1]Current Ozempic labeling, DailyMed.
- [2]Perkovic et al., “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes,” New England Journal of Medicine, 2024; PubMed PMID 38785209; NCT03819153.
- [3]NIDDK, Chronic Kidney Disease Tests & Diagnosis.
All three sources were opened and checked on July 24, 2026.